- Home
- CHNR vs JAGX Comparison
CHNR vs JAGX Comparison
Compare CHNR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- JAGX
- Stock Information
- Founded
- CHNR N/A
- JAGX 2013
- Country
- CHNR China
- JAGX United States
- Employees
- CHNR N/A
- JAGX N/A
- Industry
- CHNR Precious Metals
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- JAGX Health Care
- Exchange
- CHNR Nasdaq
- JAGX Nasdaq
- Market Cap
- CHNR 4.6M
- JAGX 3.9M
- IPO Year
- CHNR 1995
- JAGX N/A
- Fundamental
- Price
- CHNR $3.90
- JAGX $1.77
- Analyst Decision
- CHNR
- JAGX Strong Buy
- Analyst Count
- CHNR 0
- JAGX 1
- Target Price
- CHNR N/A
- JAGX $60.00
- AVG Volume (30 Days)
- CHNR 18.0K
- JAGX 147.1K
- Earning Date
- CHNR 05-15-2025
- JAGX 08-14-2025
- Dividend Yield
- CHNR N/A
- JAGX N/A
- EPS Growth
- CHNR N/A
- JAGX N/A
- EPS
- CHNR N/A
- JAGX N/A
- Revenue
- CHNR N/A
- JAGX $11,810,000.00
- Revenue This Year
- CHNR N/A
- JAGX $22.41
- Revenue Next Year
- CHNR N/A
- JAGX $30.00
- P/E Ratio
- CHNR N/A
- JAGX N/A
- Revenue Growth
- CHNR N/A
- JAGX 15.96
- 52 Week Low
- CHNR $3.16
- JAGX $1.57
- 52 Week High
- CHNR $9.04
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- CHNR 54.53
- JAGX 39.90
- Support Level
- CHNR $3.57
- JAGX $1.60
- Resistance Level
- CHNR $4.24
- JAGX $1.70
- Average True Range (ATR)
- CHNR 0.20
- JAGX 0.12
- MACD
- CHNR 0.05
- JAGX 0.01
- Stochastic Oscillator
- CHNR 59.04
- JAGX 37.04
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.